Prostaglandins and pulmonary hypertension-further evidence.
In recent years a flurry of reports have indicated that vasodilator therapy may be beneficial in patients with pulmonary hypertension. These vasodilator drugs are known to enhance prostacyclin or decrease thromboxane A2 synthesis, which may be the basis for their vasodilating affects. This implies that pulmonary vasoconstriction may be the initiating factor and that possibly prostacyclin and thromboxane A2 have a role in the pathogenesis of primary pulmonary hypertension.
D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000209:etiology*; D011453:Prostaglandins / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014661:Vasoconstriction; D014665:Vasodilator Agents / Q000494:pharmacology
D011453:Prostaglandins; D014665:Vasodilator Agents; D006830:Hydralazine